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sted that excess mortality and morbidity in womca 
may be due ta greater age or a higher prevalence of 
congestive h art failure (16). reover, in the current era of 
reperfusion therapy for acute myocardial infarction, the 
relevance of these early investigations of patients treated 
before the widespread use of thromboiytic agents i unclear. 
The major placebo-controlled trials testing efficacy of 
throm~~~~~is in acute myocardial infarction have de 
strated equivalent 30% to 50% reductions indeath in both 
men and women with reperfwsion therapy (H-14), but un- 
adjusted mortzdity rates in women h 
higher than in men. The reasons f41 
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may suffer as a result of more frequent medical comorbidi- 
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of rt-PA, urokinase, or a combination of these agents. 
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different phases of the trial. Ali patients received an intra- 
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films. Cineangiograms were subsc~u~~t~y for- 
angiographic core laboratory atthe University 
of Michigan for evaluation of infarct-related artery patency, 
residual stenosis and left icular function by sbservers 
unaware oftreatment assi n: a Abs_dutc vessel diameter 
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LAD 3s 33 
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RCA 44 48 
Other or unknown 3 6 
No. of vessels with ~50% stenosis 
(% of pts) 
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~~~~~~~~~~y (% of pts) 
within the previous 5
other293 men and 
uilar function and patency 
after administration f tb 
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In the overall cohort of 1,619 
pat nexus or surgical coronary revasculariza- 
tisn was performed in I, 138 patients (70.3%) during the 
hospital period. Women underwent revascularization onty 
slightly less frequently than men (Table 3). The proportions 
af procedures performed on an acute (including patients 
randomized to immediate coronary angioplasty in TAM1 
urgent or elective basis were comparable in the two gen 
271 men and 65 women with ocduded 
cssels at the time of acute catt._teri.zation, 
207 (76%) and 49 (75%), respectively, underwent rescue 
and 1 I (17%) were treated conservatively because they had 
anatomy unsuitable fos revascularization or relatively small 
regions of myocardium at risk. 
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t‘% of pts)” 
Lefl ventricular ejection 52.2 2 11.3 54.4 2 12.; 
fraction (%) 
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infarct zone regional wall mation -2.20 C 1.23 -2.30 2 1.26 
(SD/chord) 
Change in infarct zone motion 0.41 -c 1.00 0.41 + 1.00 
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Clinical outcome 
Death (% of pts) 5.4 9.2 0.014 
Stroke t% of pts) I .4 3.7 0.01 
Reinfarclion (% of pts) 2.6 6.4 0.005 
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Length of hospital stay Idays) 12.0 !z 19.0 14.0 ” 25.5 
Length of KU stay (days) 4.4 I 8.7 4.6 2 4.2 
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raphy from initial findings on acute cardiac catheterization. Values presented 
are mean value ? SD or percent of patients. ICU = intensive care unit; 
pts = patients, 
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char@ alive Cmm the hospitalA 
equivalent to that experienced by 
administration f streptokinase or rt 
dial infarction. This current analysis of the TA 
provides the first demonstration that thmnbolysis also pro- 
duces comparable b nefit n men and women with regard to 
infarct-related artery patency and recovery of global and 
regional left ventricular function. 
Although the efficacy of thrombolytic therapy for acute 
myocardial infarction appears to be si ilar in both men and 
women, there is evidence that his tre 
reason cited for ineligibility inthis series was age >75 years, 
dosages is c~~e~t~y u 
more recent clinical trials (3 f ,45,46). 
bleeding was not 
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were nearly identical, although nadi 
olytic therapy for acute ~~~rc~ 
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f~lufe, In contrast, he gender daerences in in-hospital 
mortality observed during this current TAMl study were not 
simifiat after clinical and an&gaphic data were factored 
into multivariate anaiysis. The influence of gender on rein- 
fatction did remain marginally significant after multivariate 
adjustment, an important finding in light of the markedly 
adverse outcome in patients with reocclusion and reinfarc- 
tii3n after thromklysis (47). 
The basis for the observed variability in prognosis for 
women after acute infarction has not been cleariy defined, 
renccs in baseline characteristics between patients 
nt analyses (20,40,41), cardiac ~athete~~at~~~ 
in 41 patients was associated with equivalent 
~urgieal nd percutaneous revascularization n 
women and men in this current report, Thus, this study 
extends previsus investigations by demonstrating theimpor- 
tant finding that in the subset of patients with acute infarc- 
tion eligible for thrsmblytic therapy, gender differences in 
the m&r clinical end paints of death and reinkrction may 
be attributable entirely to difkrences in baseline clinical and 
risk factors if coronary ~e~~~~~~~ and re- 
on are applied in a consistent manner in both 
men wad women, 
study has scvcral limitations. 
points were xamined in
knowledge of coronary anatomy. 
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